Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study of its dual-acting IL-23 inhibitor Tremfya ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...

These authors investigated the potential influence of gut microbiota on ankylosing spondylitis pathophysiology.

Johnson & Johnson announced that treatment with TREMFYA, or guselkumab, resulted in clear or almost clear skin in the majority of adults ...

Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.